Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Cho, Hongkwan ^a   Hartsock, Matthew J ^a   Xu, Zhenhua ^a   He, Meihua ^a   Duh, Elia J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fumaric acid esters monomethyl fumarate; Ischemia reperfusion; Neurodegeneration; Retina

Indexed keywords

FUMARIC ACID METHYL ESTER; TRANSCRIPTION FACTOR NRF2; FUMARIC ACID DERIVATIVE; NEUROPROTECTIVE AGENT; NFE2L2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DENDRITIC CELL; DRUG ACTIVITY; DRUG EFFICACY; ELECTRORETINOGRAPHY; GENE EXPRESSION REGULATION; GLIOSIS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MEMORY T LYMPHOCYTE; MOUSE; MUELLER CELL; NERVE CELL; NEUROPROTECTION; NONHUMAN; QUANTITATIVE ANALYSIS; REPERFUSION INJURY; RETINA ISCHEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; RETINA DEGENERATION; RETINA GANGLION CELL;

ANIMALS; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; FUMARATES; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; REPERFUSION INJURY; RETINAL DEGENERATION; RETINAL GANGLION CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84953838145     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0452-z     Document Type: Article

References (62)

1. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J (2004) Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Progress in retinal and eye research 23(1):91-147
2. Wei YH, Gong JS, Yoshida T, Eberhart CG, Xu ZH, Kombairaju P et al (2011) Nrf2 has a protective role against neuronal and capillary degeneration in retinal ischemia-reperfusion injury. Free Radical Bio Med 51(1):216-24
3. Pellegrini-Giampietro DE, Cherici G, Alesiani M, Carla V, Moroni F (1990) Excitatory amino acid release and free radical formation may cooperate in the genesis of ischemia-induced neuronal damage. The Journal of neuroscience : the official journal of the Society for Neuroscience 10(3):1035-41
4. McCord JM (1985) Oxygen-derived free radicals in postischemic tissue injury. The New England journal of medicine 312(3):159-63
5. Korthuis RJ, Granger DN (1993) Reactive oxygen metabolites, neutrophils, and the pathogenesis of ischemic-tissue/reperfusion. Clinical cardiology 16(4 Suppl 1):I19-26
6. Peng PH, Ko ML, Chen CF (2008) Epigallocatechin-3-gallate reduces retinal ischemia/reperfusion injury by attenuating neuronal nitric oxide synthase expression and activity. Experimental eye research 86(4):637-46
7. Block F, Grommes C, Kosinski C, Schmidt W, Schwarz M (1997) Retinal ischemia induced by the intraluminal suture method in rats. Neuroscience letters 232(1):45-8
8. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P et al (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain : a journal of neurology 134(Pt 3):678-92
9. Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P et al (2012) Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. The Journal of pharmacology and experimental therapeutics 341(1):274-84
10. Wang Q, Chuikov S, Taitano S, Wu Q, Rastogi A, Tuck SJ et al (2015) Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway. Int J Mol Sci 16(6):13885-907
11. Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R (2010) Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation 7:30
12. Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A et al (2012) Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation 9:163
13. Ellrichmann G, Petrasch-Parwez E, Lee DH, Reick C, Arning L, Saft C et al (2011) Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PloS one 6(1), e16172
14. Werdenberg D, Joshi R, Wolffram S, Merkle HP, Langguth P (2003) Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos 24(6):259-73
15. Bomprezzi R (2015) Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview. Ther Adv Neurol Disord 8(1):20-30
16. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. The New England journal of medicine 367(12):1087-97
17. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. The New England journal of medicine 367(12):1098-107
18. Kaspar JW, Niture SK, Jaiswal AK (2009) Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med 47(9):1304-9
19. Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annual review of pharmacology and toxicology 47:89-116
20. Bryan HK, Olayanju A, Goldring CE, Park BK (2013) The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochemical pharmacology 85(6):705-17
21. Lee DH, Gold R, Linker RA (2012) Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters. Int J Mol Sci 13(9):11783-803
22. Itoh K, Tong KI, Yamamoto M (2004) Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic Biol Med 36(10):1208-13
23. Tan SM, Deliyanti D, Figgett WA, Talia DM, de Haan JB, Wilkinson-Berka JL (2015) Ebselen by modulating oxidative stress improves hypoxia-induced macroglial Muller cell and vascular injury in the retina. Experimental eye research 136:1-8
24. Xu Z, Gong J, Maiti D, Vong L, Wu L, Schwarz JJ et al (2012) MEF2C ablation in endothelial cells reduces retinal vessel loss and suppresses pathologic retinal neovascularization in oxygen-induced retinopathy. Am J Pathol 180(6):2548-60
25. Yokota H, Narayanan SP, Zhang W, Liu H, Rojas M, Xu Z et al (2011) Neuroprotection from retinal ischemia/reperfusion injury by NOX2 NADPH oxidase deletion. Invest Ophthalmol Vis Sci 52(11):8123-31
26. Cadenas C, Franckenstein D, Schmidt M, Gehrmann M, Hermes M, Geppert B et al (2010) Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res 12(3):R44
27. Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG (2002) NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med 4(2):62-70
28. Paine A, Eiz-Vesper B, Blasczyk R, Immenschuh S (2010) Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochemical pharmacology 80(12):1895-903
29. Kalogeris T, Baines CP, Krenz M, Korthuis RJ (2012) Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol 298:229-317
30. Phillips JT, Fox RJ (2013) BG-12 in multiple sclerosis. Semin Neurol 33(1):56-65
31. Abcouwer SF, Lin CM, Shanmugam S, Muthusamy A, Barber AJ, Antonetti DA (2013) Minocycline prevents retinal inflammation and vascular permeability following ischemia-reperfusion injury. J Neuroinflammation 10:149
32. Yoneda S, Tanihara H, Kido N, Honda Y, Goto W, Hara H et al (2001) Interleukin-1beta mediates ischemic injury in the rat retina. Experimental eye research 73(5):661-7
33. Tsujikawa A, Ogura Y, Hiroshiba N, Miyamoto K, Kiryu J, Tojo SJ et al (1999) Retinal ischemia-reperfusion injury attenuated by blocking of adhesion molecules of vascular endothelium. Invest Ophthalmol Vis Sci 40(6):1183-90
34. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA (1994) Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 91(9):3652-6
35. Charo IF, Taubman MB (2004) Chemokines in the pathogenesis of vascular disease. Circ Res 95(9):858-66
36. Lee PY, Li Y, Kumagai Y, Xu Y, Weinstein JS, Kellner ES et al (2009) Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. Am J Pathol 175(5):2023-33
37. Wetzel K, Struyf S, Van Damme J, Kayser T, Vecchi A, Sozzani S et al (2007) MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells. Int J Cancer 120(6):1364-71
38. Moore BB, Murray L, Das A, Wilke CA, Herrygers AB, Toews GB (2006) The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol 35(2):175-81
39. Chu HX, Arumugam TV, Gelderblom M, Magnus T, Drummond GR, Sobey CG (2014) Role of CCR2 in inflammatory conditions of the central nervous system. J Cereb Blood Flow Metab 34(9):1425-9
40. Fletcher EL, Downie LE, Hatzopoulos K, Vessey KA, Ward MM, Chow CL et al (2010) The significance of neuronal and glial cell changes in the rat retina during oxygen-induced retinopathy. Doc Ophthalmol 120(1):67-86
41. Prentice HM, Biswal MR, Dorey CK, Blanks JC (2011) Hypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease. Invest Ophthalmol Vis Sci 52(12):8562-70
42. Bozard BR, Chothe PP, Tawfik A, Williams C, Fulzele S, Prasad PD et al (2012) Regulation of proton-coupled folate transporter in retinal Muller cells by the antipsoriatic drug monomethylfumarate. Glia 60(3):333-42
43. Bringmann A, Pannicke T, Grosche J, Francke M, Wiedemann P, Skatchkov SN et al (2006) Muller cells in the healthy and diseased retina. Progress in retinal and eye research 25(4):397-424
44. Xu Z, Cho H, Hartsock M, Mitchell KL, Gong J, Wu L et al (2015) Neuroprotective role of Nrf2 for retinal ganglion cells in ischemia-reperfusion. Journal of neurochemistry
45. Promsote W, Makala L, Li B, Smith SB, Singh N, Ganapathy V et al (2014) Monomethylfumarate induces gamma-globin expression and fetal hemoglobin production in cultured human retinal pigment epithelial (RPE) and erythroid cells, and in intact retina. Invest Ophthalmol Vis Sci 55(8):5382-93
46. Ananth S, Babu E, Veeranan-Karmegam R, Bozard Baldowski BR, Boettger T, Martin PM (2013) Induction of the cystine/glutamate exchanger SLC7A11 in retinal pigment epithelial cells by the antipsoriatic drug monomethylfumarate. Invest Ophthalmol Vis Sci 54(3):1592-602
47. Ashrafian H, Czibik G, Bellahcene M, Aksentijevic D, Smith AC, Mitchell SJ et al (2012) Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab 15(3):361-71
48. Zhao X, Sun G, Zhang J, Ting SM, Gonzales N, Aronowski J (2015) Dimethyl Fumarate Protects Brain From Damage Produced by Intracerebral Hemorrhage by Mechanism Involving Nrf2. Stroke 46(7):1923-8
49. Sofroniew MV (2005) Reactive astrocytes in neural repair and protection. Neuroscientist 11(5):400-7
50. Bringmann A, Iandiev I, Pannicke T, Wurm A, Hollborn M, Wiedemann P et al (2009) Cellular signaling and factors involved in Muller cell gliosis: neuroprotective and detrimental effects. Progress in retinal and eye research 28(6):423-51
51. Dyer MA, Cepko CL (2000) Control of Muller glial cell proliferation and activation following retinal injury. Nat Neurosci 3(9):873-80
52. Xu ZH, Wei YH, Gong JS, Cho H, Park JK, Sung ER et al (2014) NRF2 plays a protective role in diabetic retinopathy in mice. Diabetologia 57(1):204-13
53. Marco FD, Romeo S, Nandasena C, Purushothuman S, Adams C, Bisti S et al (2013) The time course of action of two neuroprotectants, dietary saffron and photobiomodulation, assessed in the rat retina. Am J Neurodegener Dis 2(3):208-20
54. Di Marco F, Di Paolo M, Romeo S, Colecchi L, Fiorani L, Spana S et al (2014) Combining neuroprotectants in a model of retinal degeneration: no additive benefit. PloS one 9(6), e100389
55. Kim JH, Kim JH, Lee YM, Ahn EM, Kim KW, Yu YS (2009) Decursin inhibits VEGF-mediated inner blood-retinal barrier breakdown by suppression of VEGFR-2 activation. J Cereb Blood Flow Metab 29(9):1559-67
56. Koto T, Takubo K, Ishida S, Shinoda H, Inoue M, Tsubota K et al (2007) Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. Am J Pathol 170(4):1389-97
57. Block F, Schwarz M (1998) The b-wave of the electroretinogram as an index of retinal ischemia. Gen Pharmacol 30(3):281-7
58. Gurevich L, Slaughter MM (1993) Comparison of the waveforms of the ON bipolar neuron and the b-wave of the electroretinogram. Vision Res 33(17):2431-5
59. Gillard GO, Collette B, Anderson J, Chao J, Scannevin RH, Huss DJ et al (2015) DMF, but not other fumarates, inhibits NF-kappaB activity in vitro in an Nrf2-independent manner. J Neuroimmunol 283:74-85
60. Brennan M, Allaire N, Huss D, Cullen P, Thai A, Szak S et al. Dimethyl Fumarate and Monomethyl Fumarate are Distinguished by Non-Overlapping Pharmacodynamic Effects In Vivo (P1.206). Neurology. 2014;82(10 Supplement):P1.206.
61. Rostami-Yazdi M, Clement B, Mrowietz U (2010) Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch Dermatol Res 302(7):531-8
62. Gao B, Doan A, Hybertson BM (2014) The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders. Clin Pharmacol 6:19-34